Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Shares Outstanding (2016 - 2025)

Avanos Medical (AVNS) has disclosed Shares Outstanding for 12 consecutive years, with $46.5 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 1.07% to $46.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $46.5 million through Dec 2025, up 1.07% year-over-year, with the annual reading at $46.5 million for FY2025, 1.07% up from the prior year.
  • Shares Outstanding hit $46.5 million in Q4 2025 for Avanos Medical, roughly flat from $46.4 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $48.2 million in Q4 2021 to a low of $45.9 million in Q2 2024.
  • Historically, Shares Outstanding has averaged $46.8 million across 5 years, with a median of $46.5 million in 2022.
  • Biggest five-year swings in Shares Outstanding: fell 3.48% in 2022 and later increased 1.07% in 2025.
  • Year by year, Shares Outstanding stood at $48.2 million in 2021, then decreased by 3.48% to $46.5 million in 2022, then fell by 0.76% to $46.2 million in 2023, then decreased by 0.46% to $46.0 million in 2024, then increased by 1.07% to $46.5 million in 2025.
  • Business Quant data shows Shares Outstanding for AVNS at $46.5 million in Q4 2025, $46.4 million in Q3 2025, and $46.3 million in Q2 2025.